Ozempic (semaglutide) injection
Once-weekly semaglutide injection from Novo Nordisk, FDA-approved for type 2 diabetes and related heart and kidney risk reduction. Not approved for weight management. Self-pay…
TirzaSema has no affiliate or commercial relationship with Novo Nordisk.
Novo Nordisk is a Danish pharmaceutical company that makes the semaglutide medicines Wegovy and Ozempic. In the United States, it sells these medicines to self-pay patients through NovoCare Pharmacy, its direct-to-patient pharmacy service.
TirzaSema has no affiliate or commercial relationship with Novo Nordisk.
Once-weekly semaglutide injection from Novo Nordisk, FDA-approved for type 2 diabetes and related heart and kidney risk reduction. Not approved for weight management. Self-pay…
Once-weekly semaglutide injection from Novo Nordisk. FDA-approved for chronic weight management, cardiovascular risk reduction and noncirrhotic MASH with fibrosis. Self-pay from $349/month via NovoCare…
Once-daily oral semaglutide tablet from Novo Nordisk, FDA-approved December 2025 for weight management and cardiovascular risk reduction in adults. Self-pay $149 to $299/month by…